β-Lapachone attenuates mitochondrial dysfunction in MELAS cybrid cells.

Area of Science:

• Biochemistry
• Cell Biology
• Genetics

Background:

• Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a severe mitochondrial disease.
• Caused by mutations in the mitochondrial genome, MELAS leads to significant cellular dysfunction.

Purpose of the Study:

• To investigate the therapeutic potential of β-lapachone (β-lap) in MELAS cybrid cells.
• To compare the efficacy of β-lap with other quinone compounds like idebenone and CoQ10.

Main Methods:

• Utilized MELAS cybrid cells to model the disease.
• Assessed mitochondrial function, including energy production, membrane potential, and reactive oxygen species (ROS) levels.
• Measured lactic acidosis, glucose uptake, and Sirt1 activation via NAD(+)/NADH ratio.
• Quantified mitochondrial DNA (mtDNA) content.

Main Results:

• β-lapachone significantly restored energy production and mitochondrial membrane potential in MELAS cybrid cells.
• β-lap normalized elevated ROS levels, reduced lactic acidosis, and improved glucose uptake.
• β-lap activated Sirt1 by increasing the NAD(+)/NADH ratio, leading to increased mtDNA content.
• Idebenone and CoQ10 showed minimal effects in this study.

Conclusions:

• β-lapachone demonstrates significant efficacy in rescuing mitochondrial dysfunction in MELAS cybrid cells.
• β-lap may represent a novel therapeutic strategy for treating MELAS, surpassing existing quinone treatments.
• Further research into β-lap as a MELAS therapeutic is warranted.